8-K: Arcellx Announces Positive Phase 2 iMMagine-1 Study Data for Anito-cel in Relapsed/Refractory Multiple Myeloma

Arcellx reports promising results from its Phase 2 iMMagine-1 study of anito-cel, demonstrating high overall response rates and manageable safety in patients with relapsed or refractory multiple myeloma.

Summary

• Arcellx announced positive data from its Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed and/or refractory multiple myeloma (RRMM).
• The data, from a May 1, 2025 data cutoff, includes all 117 patients with a median follow-up of 12.6 months.
• The overall response rate (ORR) was 97% (114/117), with a complete response/stringent complete response (CR/sCR) rate of 68% (79/117).
• The very good partial response or higher (VGPR) rate was 85% (100/117).
• 93.3% (70/75) of evaluable patients achieved minimal residual disease (MRD) negativity.
• Six-month progression-free survival (PFS) and overall survival (OS) rates were 91.9% and 96.6%, respectively.
• 12-month PFS and OS rates were 78.8% and 95.2%, respectively.
• No delayed neurotoxicities, including Parkinsonism, cranial nerve palsies, or Guillain-Barr syndrome, and no immune-mediated enterocolitis were observed.
• The company plans to present the data at the EHA 2025 Congress on June 14, 2025.
• Arcellx anticipates a commercial launch of anito-cel in 2026 in partnership with Kite, a Gilead Company.

Sentiment

Score: 9

Explanation: The document presents highly positive clinical data, indicating strong efficacy and a favorable safety profile for anito-cel. The planned commercial launch and partnership with Kite further contribute to a positive outlook.

Positives

• High overall response rate (97%) and complete response rate (68%) indicate strong efficacy.
• High MRD negativity rate (93.3%) suggests deep and durable responses.
• Favorable safety profile with no delayed neurotoxicities or immune-mediated enterocolitis observed.
• High six-month and twelve-month PFS and OS rates demonstrate promising survival benefits.
• Partnership with Kite, a Gilead Company, provides commercialization support.
• Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the FDA.

Risks

• The forward-looking statements are subject to risks and uncertainties as detailed in Arcellx's SEC filings.
• Commercial launch in 2026 is subject to regulatory approvals and market conditions.

Future Outlook

Arcellx plans to present the iMMagine-1 data at the EHA 2025 Congress and is preparing for a commercial launch of anito-cel in 2026 in partnership with Kite.

Management Comments

• Rami Elghandour, Arcellx's Chairman and CEO, stated that the clinical data supports the belief that anito-cel has the potential to address the needs of myeloma patients.
• Elghandour highlighted the unmet medical need for efficacious, safe, and accessible CAR-T therapies and believes anito-cel can address these needs.

Industry Context

The announcement highlights the ongoing development of CAR-T therapies for multiple myeloma, a competitive field with significant unmet medical needs. Arcellx's anito-cel aims to differentiate itself through its novel D-Domain binder and favorable safety profile.

Comparison to Industry Standards

• The 97% ORR and 68% CR/sCR rates are highly competitive compared to existing CAR-T therapies for RRMM, such as Abecma (idecabtagene vicleucel) from Bristol Myers Squibb and Carvykti (ciltacabtagene autoleucel) from Legend Biotech and Janssen.
• Abecma and Carvykti have shown ORRs in the range of 70-90% and CR/sCR rates between 30-40% in their respective clinical trials.
• The absence of delayed neurotoxicities with anito-cel is a notable advantage, as neurotoxicity is a known risk with other CAR-T therapies.
• The MRD negativity rate of 93.3% is also very promising, suggesting a potential for deep and durable remissions, which is a key goal in myeloma treatment.

Stakeholder Impact

• Positive results could lead to improved treatment options and outcomes for patients with relapsed/refractory multiple myeloma.
• Successful commercialization of anito-cel could generate significant revenue for Arcellx and Kite.
• The positive data may increase shareholder value for Arcellx.

Next Steps

• Presentation of iMMagine-1 data at the EHA 2025 Congress on June 14, 2025.
• Continued development of anito-cel in Phase 2 and Phase 3 studies.
• Preparation for commercial launch of anito-cel in 2026.
• Collaboration with Kite for commercialization in the United States and globally.

Key Dates

Keywords

anito-cel, multiple myeloma, Arcellx, Kite, CAR-T therapy, iMMagine-1 study, relapsed/refractory, clinical data, EHA 2025, FDA